Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity.

Huang YJ, Lane HY, Lin CH.

Neural Plast. 2017;2017:4605971. doi: 10.1155/2017/4605971. Epub 2017 Apr 11. Review.

2.

Clozapine counteracts a ketamine-induced depression of hippocampal-prefrontal neuroplasticity and alters signaling pathway phosphorylation.

Rame M, Caudal D, Schenker E, Svenningsson P, Spedding M, Jay TM, Godsil BP.

PLoS One. 2017 May 4;12(5):e0177036. doi: 10.1371/journal.pone.0177036. eCollection 2017.

3.

Genetic Deletion of Akt3 Induces an Endophenotype Reminiscent of Psychiatric Manifestations in Mice.

Bergeron Y, Bureau G, Laurier-Laurin MÉ, Asselin E, Massicotte G, Cyr M.

Front Mol Neurosci. 2017 Apr 10;10:102. doi: 10.3389/fnmol.2017.00102. eCollection 2017.

4.

Modulation of the activity of N-methyl-d-aspartate receptors as a novel treatment option for depression: current clinical evidence and therapeutic potential of rapastinel (GLYX-13).

Vasilescu AN, Schweinfurth N, Borgwardt S, Gass P, Lang UE, Inta D, Eckart S.

Neuropsychiatr Dis Treat. 2017 Mar 31;13:973-980. doi: 10.2147/NDT.S119004. eCollection 2017. Review.

5.

Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression.

Lener MS, Kadriu B, Zarate CA Jr.

Drugs. 2017 Mar;77(4):381-401. doi: 10.1007/s40265-017-0702-8. Review.

PMID:
28194724
6.

GSK-3: A key regulatory target for ketamine's rapid antidepressant effects mediated by enhanced AMPA to NMDA throughput.

Zarate CA Jr, Machado-Vieira R.

Bipolar Disord. 2016 Dec;18(8):702-705. doi: 10.1111/bdi.12452. Epub 2016 Nov 29. No abstract available.

PMID:
27900801
7.

Ketamine up-regulates a cluster of intronic miRNAs within the serotonin receptor 2C gene by inhibiting glycogen synthase kinase-3.

Grieco SF, Velmeshev D, Magistri M, Eldar-Finkelman H, Faghihi MA, Jope RS, Beurel E.

World J Biol Psychiatry. 2016 Oct 10:1-12. [Epub ahead of print]

PMID:
27723376
8.

Ketamine-induced inhibition of glycogen synthase kinase-3 contributes to the augmentation of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor signaling.

Beurel E, Grieco SF, Amadei C, Downey K, Jope RS.

Bipolar Disord. 2016 Sep;18(6):473-480. doi: 10.1111/bdi.12436. Epub 2016 Sep 30.

PMID:
27687706
9.

The interactive effects of ketamine and magnesium upon depressive-like pathology.

Razmjou S, Litteljohn D, Rudyk C, Syed S, Clarke M, Pentz R, Dwyer Z, Hayley S.

Neuropsychiatr Dis Treat. 2016 Sep 8;12:2049-56. doi: 10.2147/NDT.S111131. eCollection 2016.

10.

The antidepressant roles of Wnt2 and Wnt3 in stress-induced depression-like behaviors.

Zhou WJ, Xu N, Kong L, Sun SC, Xu XF, Jia MZ, Wang Y, Chen ZY.

Transl Psychiatry. 2016 Sep 13;6(9):e892. doi: 10.1038/tp.2016.122.

11.

Up-regulation of insulin-like growth factor 2 by ketamine requires glycogen synthase kinase-3 inhibition.

Grieco SF, Cheng Y, Eldar-Finkelman H, Jope RS, Beurel E.

Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jan 4;72:49-54. doi: 10.1016/j.pnpbp.2016.08.008. Epub 2016 Aug 16.

PMID:
27542584
12.

Practical application of the neuroregenerative properties of ketamine: real world treatment experience.

Henderson TA.

Neural Regen Res. 2016 Feb;11(2):195-200. doi: 10.4103/1673-5374.177708. Review.

13.

KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS.

Abdallah CG, Adams TG, Kelmendi B, Esterlis I, Sanacora G, Krystal JH.

Depress Anxiety. 2016 Aug;33(8):689-97. doi: 10.1002/da.22501. Epub 2016 Apr 6. Review.

PMID:
27062302
14.

Current Status of Ketamine and Related Therapies for Mood and Anxiety Disorders.

Costi S, Van Dam NT, Murrough JW.

Curr Behav Neurosci Rep. 2015 Dec;2(4):216-225. Epub 2015 Oct 1.

15.

GSK3β isoform-selective regulation of depression, memory and hippocampal cell proliferation.

Pardo M, Abrial E, Jope RS, Beurel E.

Genes Brain Behav. 2016 Mar;15(3):348-55. doi: 10.1111/gbb.12283. Epub 2016 Feb 12.

16.

Previous Ketamine Produces an Enduring Blockade of Neurochemical and Behavioral Effects of Uncontrollable Stress.

Amat J, Dolzani SD, Tilden S, Christianson JP, Kubala KH, Bartholomay K, Sperr K, Ciancio N, Watkins LR, Maier SF.

J Neurosci. 2016 Jan 6;36(1):153-61. doi: 10.1523/JNEUROSCI.3114-15.2016.

17.

New targets for rapid antidepressant action.

Machado-Vieira R, Henter ID, Zarate CA Jr.

Prog Neurobiol. 2017 May;152:21-37. doi: 10.1016/j.pneurobio.2015.12.001. Epub 2015 Dec 23. Review.

PMID:
26724279
18.

New perspectives on the involvement of mTOR in depression as well as in the action of antidepressant drugs.

Ignácio ZM, Réus GZ, Arent CO, Abelaira HM, Pitcher MR, Quevedo J.

Br J Clin Pharmacol. 2016 Nov;82(5):1280-1290. doi: 10.1111/bcp.12845. Epub 2016 Jan 8. Review.

PMID:
26613210
19.

BDNF - a key transducer of antidepressant effects.

Björkholm C, Monteggia LM.

Neuropharmacology. 2016 Mar;102:72-9. doi: 10.1016/j.neuropharm.2015.10.034. Epub 2015 Nov 11. Review.

20.

Supplemental Content

Support Center